BURLINGTON, Mass., Oct. 8, 2026 /PRNewswire/ -- Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that management will participate in two upcoming industry conferences to highlight C-1101, the company's novel, platelet-derived multi-protein biologic therapeutic designed to treat lumbosacral radiculopathy (LSR), or chronic sciatica.
Consano Bio to Highlight C-1101, Its Potential First-in-Class Disease-Modifying Therapeutic for Chronic Sciatica, at Upcoming October Conferences
2 min read Premium comments
pain managementConsano Bioplatelet-derived multi-protein biologic therapeuticlumbosacral radiculopathychronic sciaticaconferences
On October 15, 2026, Consano Bio will present at Align Summit, MassBio's annual partnering conference, in Boston, MA, and on October 28, 2026, management will participate in a panel discussion at the BioFuture conference in New York, NY.
Details are as follows:
Event: | Align Summit, MassBio's Annual Partnering Conference |
Date: | October 15, 2026 |
Presentation Track: | Advanced Biologics & Protein Therapeutics |
Presentation Time & | 1:40 – 2:00 PM, ET, Constitution A |
Event: | BioFuture |
Date: | October 28-29, 2026 |
Panel Title: | BioFuture Now: Pioneering the Future of Biopharma Breakthroughs |
Panel Time & | October 28, 10:00-10:55 AM, ET, Spotlight Panel 4A |
During each conference, management will meet with registered investors and potential partners to present Consano Bio's business and clinical development strategy, highlight recent corporate achievements, and discuss anticipated milestones.
About Chronic Lumbosacral Radiculopathy (LSR)
Chronic, painful LSR, or chronic sciatica, is a chronic lower back pain condition caused by damage or irritation of spinal nerve roots in the lower back, leading to radiating pain, numbness, and weakness from the spine into the leg. There are no FDA-approved pharmaceutical treatments for chronic sciatica despite its prevalence and widespread societal and economic impact.
About C-1101
C-1101 is Consano Bio's lead investigational clinical candidate and the first pharmaceutical therapy of its kind in development: a novel, platelet-derived multi-protein biologic therapeutic. It is designed to treat LSR, or chronic sciatica, by modulating inflammation and stimulating and enhancing cellular repair at the site of injury. The product contains consistent concentrations of cytokines, growth factors, and matrix proteins designed to help trigger the body's natural healing response. Delivered via an epidural injection, C-1101 is intended to provide supraphysiologic concentrations of these proteins directly to the site of nerve injury.
About Consano Bio
Consano Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of painful and debilitating orthopedic conditions through a new class of multi-protein biologic therapeutics. The company is headquartered in the Greater Boston area. For more information, visit www.consanobio.com.
Contacts:
Consano Bio
Rahul Bansal
VP, Finance & Investor Relations
rbansal@consanobio.com
(908) 230-6689
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
SOURCE Consano Bio
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Consano Bio is strategically showcasing C-1101, a potential first-in-class therapeutic for chronic sciatica, at upcoming industry conferences to attract investors and partners. This highlights a clear strategy to address a significant unmet market need, as there are currently no FDA-approved pharmaceutical treatments for this prevalent condition. Successful clinical development and market adoption could position C-1101 as a disruptive solution.
- Consano Bio aims to capitalize on the lack of FDA-approved treatments for chronic sciatica, presenting a substantial market opportunity.
- Conference participation targets investor and partner engagement, crucial for funding and commercialization strategy.
PhD Lens: Clinical and outcomes impact
C-1101 is Consano Bio's lead investigational, platelet-derived multi-protein biologic therapeutic for chronic sciatica (LSR). Its mechanism involves modulating inflammation and stimulating cellular repair at the site of spinal nerve root injury. Delivered via epidural injection, C-1101 provides supraphysiologic concentrations of cytokines, growth factors, and matrix proteins to trigger natural healing responses. It represents a novel approach to a condition lacking pharmaceutical treatments.
- C-1101 is a multi-protein biologic containing consistent concentrations of cytokines, growth factors, and matrix proteins.
- The therapeutic is designed to modulate inflammation and enhance cellular repair at the lumbosacral nerve root injury site.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.